Entera Bio Ltd. (ENTX)
NASDAQ: ENTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ENTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $575.53M
- EPS (TTM)
- -$0.40
- Dividend yield
- None
- 52-week range
- 0.91 – 4.20
- Day range
- 3.18 – 3.32
- Volume / Avg
- 468.44K / 438.35K
- Beta
- —
- Shares outstanding
- 174.14M
52-week range
ENTX stock today
Shares of Entera Bio (ENTX) finished higher on Nov 20 at $3.31, a gain of 0.76% or $0.025 per share, versus the S&P 500's 3.70% decline. Shares are 21.3% below their 52-week high of $4.20, set on Jul 27, 2026 and 263.2% above the 52-week low of $0.91, in the middle of the past year's range. ENTX is up 70.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 30.6%.
Entera Bio has posted a net loss over the last twelve months (EPS of -$0.40), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Entera Bio
Company profileEntera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Ms. Miranda J. Toledano M.B.A.
- Headquarters
- Jerusalem
- Employees
- 27
- IPO year
- 2018
- Website
- enterabio.com
Financial highlights
Full financialsIn fiscal 2025, Entera Bio generated $42,000 in revenue, down 76.8% from fiscal 2024, its first annual decline since 2023. Entera Bio reported a net loss of $11.4 million, compared with a loss of $9.5 million a year earlier. Gross margin was 0.0% (down from 5.0%) and operating margin -27450.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $42.00K | $181.00K | $0 | $134.00K | $571.00K |
| Growth | -76.80% | — | -100.00% | -76.53% | +56.44% |
| Net income | $-11.44M | $-9.54M | $-8.89M | $-13.07M | $-12.19M |
| EPS (diluted) | $0.25 | $0.25 | $0.31 | $0.45 | $0.47 |
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$9.75+195.01%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $0.11 vs —
ENTX news
All ENTX news- Entera Bio Q3 Loss Widens; Expects Phase 3 Osteoporosis Topline Data In H2'28NasdaqENTX, BRK.B
- Entera Bio GAAP EPS of -$0.11 misses by $0.04Seeking Alpha
- Entera Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswire
- Entera Bio Ltd. Appoints Dr. Juan Camilo Arjona Ferreira to Board of DirectorsNasdaq
- Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual MeetingGlobeNewswire
- Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingGlobeNewswire
Entera Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs ENTX |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs ENTX |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs ENTX |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs ENTX |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs ENTX |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs ENTX |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs ENTX |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs ENTX |
Indexes, lists and sector
Entera Bio stock FAQ
What is Entera Bio's stock price today?
ENTX last traded at $3.31 as of Nov 20, 4:00 PM EST, up 0.76% on the day. Prices are delayed at least 15 minutes.
Who is Entera Bio's CEO?
Ms. Miranda J. Toledano M.B.A. is the chief executive officer of Entera Bio Ltd., which has about 27 employees.
What is the ENTX 52-week high?
The 52-week high for ENTX is $4.20 and the 52-week low is $0.91. The stock is currently 21.3% below its high.